Replies to post #8758 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

ML has been saying this for some time, publicly and privately, so today’s statement on Copaxone is nothing new.

p.s. Most sell-side analysts agree with ML, which is probably a good thing vis-à-vis the expectations baked into the share price.

[Regulardoc]

Either the reporter of this story is unknowing, or the ML analysts don't know their science. As Dew would offer, "who can point out the error in this report?"

Note: excluding any prediction of outcome